FDA Says It Has Received 990 Adverse Event Reports Tied To Compounded Semaglutide And More Than 730 Tied To Compounded Tirzepatide; Establishes Import Alert For Compounded GLP-1 Active Pharmaceutical Ingredients

Benzinga Newsdesk www.benzinga.com Neutral 80.0%

Neg 0% Neu 80% Pos 0%

https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss

Comments

No comments yet. Be the first!